0 results for 'Eli Lilly'
DeSantis Blasts FDA For Halting Drugs Ineffective on Omicron
The FDA says omicron is responsible for more than 99% of U.S. infections, making it "highly unlikely" that the antibodies would be effective for people seeking treatment.Run It Back! One Last Look at the 2021 Litigators of the Week
Here's one last 'huzzah!' for this year's winners.Health-Care Giant J&J to Split Into Drug, Consumer Companies
Johnson & Johnson is following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market.See Who Passed the July 2021 New York Bar Exam
The New York State Board of Law Examiners examined 9,227 candidates during the July 27-28 examination. Of those candidates, 5,791 passed for an overall passing rate of 63%.A Quiet US Supreme Court Term Ahead for IP—With One Potential Explosion
Stanford law professor Mark Lemley said he believes the justices would much prefer not to wade back into patent eligibility. But, he said, American Axle and Manufacturing v. Neapco "has an interesting spin because it will look to the justices like real technology, not the weak patents they have encountered before."View more book results for the query "Eli Lilly"
A Quiet US Supreme Court Term Ahead for IP—With One Potential Explosion
The court is seeking the solicitor general's views on a case that could reset the court's much-maligned patent eligibility law. Beyond that, a fair use case over Andy Warhol artwork and patent dispute over biologic drugs offer a chance of fireworks.G and G Oil Co. of Ind. v. Cont'l W. Ins. Co.
Tips for pursuing coverage for damages and liabilities stemming from a cyberattack.Governor Pledges to 'Fight Like Hell' Over COVID-19 Treatment
Gov. Ron DeSantis said that the White House's plan to assume a role as distributor for monoclonal antibody treatments will result in fewer therapeutics coming to the state.DeSantis Pledges to 'Fight Like Hell' Over COVID-19 Treatment
Gov. Ron DeSantis said that the White House's plan to assume a role as distributor for monoclonal antibody treatments will result in fewer therapeutics coming to the state.Pay for Pharmaceutical Industry GCs Picked Up Amid Pandemic
Surging interest in pharmaceuticals has created more competition for top GCs among life sciences companies.State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now
2024 ESI Risk Management & Litigation Readiness Report
Brought to you by Pagefreezer
Download Now
Creating a Culture of Compliance
Brought to you by Ironclad
Download Now
A Buyer's Guide to Law Firm Software
Brought to you by PracticePanther
Download Now